Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy

Table 1 Demographics and clinicopathological data on 191 patients with gastric cancer with respect to No. 10 LN metastasis n (%)

		Metastasis positive	Metastasis negative	Total	P value
		20 (10.5)	171 (89.5)	191 (100)
Gender	Male	14 (70.0)	111 (64.9)	125 (65.4)	0.651
	Female	6 (30.0)	60 (35.1)	66 (34.5)
Age (years)	≤ 60	7 ( 35.0)	107 (62.6)	114 (59.7)	0.017
	> 60	13 (65.0)	64 (37.4)	77 (40.3)
Site	L	1 (5.0)	11 ( 6.4)	12 (6.3)	0.616
	M	9 (45.0)	58 (33.9)	67 (35.1)
	U	10 (50.0)	102 (59.6)	112 (58.6)
Number of site	1	5 (25.0)	41 (24.0)	46 (24.1)	0.008
	2	7 (35.0)	78 (45.6)	85 (44.5)
	≤ 3	8 (40.0)	52 (30.4)	60 (31.4)
Location	Less	0 ( 0.0)	73 (42.7)	73 (38.2)	< 0.001
	Ant	1 (5.0)	15 (8.8)	16 (8.4)
	Post	3 (15.0)	32 (18.7)	35 (18.3)
	Great	8 (40.0)	13 (7.6)	21 (11.0)
	Cir	8 (40.0)	38 (22.2)	46 (24.1)
Number of location	1	7 (35.0)	90 (52.6)	97 (50.8)	0.200
	2	2 (10.0)	28 (16.4)	30 (15.7)
	3	3 (15.0)	15 (8.8)	18 (9.4)
	4	8 (40.0)	38 (22.2)	46 (24.1)
Tumor size (mm)	≤ 100	11 (55.0)	65 (38.0)	76 (39.8)	0.142
	> 100	9 (45.0)	106 (62.0)	115 (60.2)
Macroscopic type	0	2 (10.0)	13 (7.6)	15 (7.9)	0.503
	1	1 (5.0)	5 (2.9)	6 (3.1)
	2	2 (10.0)	44 (25.7)	46 (24.1)
	3	10 (50.0)	69 (40.4)	79 (41.4)
	4	5 (25.0)	30 (17.5)	35 (18.3)
	5	0 (0.0)	10 (5.8)	10 (5.2)
Histological type	Differentiat	3 (15.0)	53 (31.0)	56 (29.3)	0.137
	Undifferentiated	17 (85.0)	118 (69.0)	135 (70.7)
Depth	M, SM	1 (5.0)	10 (5.8)	11 (5.6)	0.020
	MP	0 (0.0)	12 (7.0)	12 (6.3)
	SS	2 (10.0)	17 (9.9)	19 (9.9)
	SE	9 (45.0)	111 (64.9)	120 (62.8)
	SI	8 (40.0)	21 (12.3)	29 (15.2)
Ly	0, 1	1 (5.0)	48 (28.1)	49 (25.7)	0.025
	2, 3	19 (95.0)	123 (71.9)	142 (74.3)
V	-	2 (10.0)	50 (29.2)	52 (27.2)	0.067
	+	18 (90.0)	121 (70.8)	139 (72.8)
Stromal volume	Med	3 (15.0)	60 (35.1)	63 (33.0)	0.147
	Int	8 (40.0)	62 (36.3)	70 (36.6)
	Sci	9 (45.0)	49 (28.7)	58 (30.4)
INF	α	1 (5.0)	42 (24.6)	43 (22.5)	0.127
	β	6 (30.0)	47 (27.5)	53 (27.7)
	γ	13 (65.0)	82 (48.0)	95 (49.7)
N	0	0 (0.0)	60 (35.1)	60 (31.4)	< 0.001
	1	2 (10.0)	50 (29.2)	52 (27.2)
	2	12 (60.0)	40 (23.4)	52 (27.2)
	3	6 (30.0)	18 (10.5)	24 (12.6)
	M	0 (0.0)	3 (1.8)	3 (1.6)
Number of N	0	0 (0.0)	60 (35.1)	60 (31.4)	0.003
	1-6	7 (35.0)	55 (32.2)	62 (32.5)
	7-15	6 (30.0)	34 (19.9)	40 (20.9)
	16-	7 (35.0)	22 (12.9)	29 (15.2)
Stage	IA,IB	0 (0.0)	25 (14.6)	25 (13.1)	< 0.001
	II	1 (5.0)	39 (22.8)	40 (20.9)
	IIIA	1 (5.0)	45 (26.3)	46 (24.1)
	IIIB	4 (20.0)	35 (20.5)	39 (20.4)
	IV	14 (70.0)	27 (15.8)	41 (21.5)

Various clinicopathological factors, including gender, age, site, the number of sites (Number of sites), location, the number of locations (Number of locations), tumor size, macroscopic type, and histological type were evaluated for any independent contributions to No. 10 LN metastasis, depth of invasion (Depth), invasion of lymph vessel (Ly), venous invasion (V), stromal volume, pattern of tumor infiltration (INF), N factor (N), the number of lymph nodes with positive metastasis (Number of N), and stage using the χ² test. Age, Number of sites, Location, Depth, Ly, N, Number of N, and Stage were found to differ significantly between the Positive Group and the Negative Group (P = 0.017, P = 0.008, P < 0.001, P = 0.017, P = 0.008, P < 0.001, P = 0.003, and P < 0.001, respectively).